Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21870605 | 0.95 | PIK3CD (0.52) | PIK3CDHRH3CYP2D6SMN1; SMN2POLB | |
| SCHEMBL18926695 | 0.85 | PIK3CD (0.58) | PIK3CDHRH3CYP2D6SMN1; SMN2POLB | |
| SCHEMBL29328614 | 0.80 | GBA1 (0.36) | PIK3CDSMN1; SMN2POLB | |
| SCHEMBL25124999 | 0.79 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL3423064 | 0.78 | PIK3CD (0.53) | PIK3CDHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL24842077 | 0.78 | PIK3CD (0.52) | PIK3CDHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL24841928 | 0.78 | PIK3CD (0.58) | PIK3CDHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL3420067 | 0.77 | PIK3CD (0.42) | PIK3CDHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL23716220 | 0.76 | PIK3CD (0.50) | PIK3CDHRH3CYP2D6SMN1; SMN2 | |
| SCHEMBL17285927 | 0.76 | PIK3CD (0.50) | PIK3CDHRH3CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230129164-A1 | NOVEL USE OF MULTIKINASE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230118688-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-20 | — | — | US | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2020061375-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | SPOUT1, MRPL21, NRDC | PIK3CD 913/4885HRH3 3748/4885CYP2D6 2814/4885 |
| US-20230118688-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | PIK3CD 1225/4885HRH3 376/4885CYP2D6 3927/4885 |
| US-20230129164-A1 | NOVEL USE OF MULTIKINASE INHIBITOR | MAP2K5, MAP3K11, MAP3K1 | PIK3CD 96/4885HRH3 4070/4885CYP2D6 2986/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | PIK3CD 1321/4885HRH3 211/4885CYP2D6 128/4885 |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | MAP3K1, MAP3K5, MAP3K2 | PIK3CD 572/4885HRH3 2008/4885CYP2D6 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.